{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:30:58Z","timestamp":1787610658777,"version":"build-2736575974"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Adequate oxygen levels are essential for the functioning and maintenance of biological processes in virtually every cell, albeit based on specific need. Thus, any change in oxygen pressure leads to modulated activation of the hypoxia pathway, which affects numerous physiological and pathological processes, including hematopoiesis, inflammation, and tumor development. The Hypoxia Inducible Factors (HIFs) are essential transcription factors and the driving force of the hypoxia pathway; whereas, their inhibitors, HIF prolyl hydroxylase domain (PHDs) proteins are the true oxygen sensors that critically regulate this response. Recently, we and others have described the central role of the PHD\/HIF axis in various compartments of the adrenal gland and its potential influence in associated tumors, including pheochromocytomas and paragangliomas. Here, we provide an overview of the most recent findings on the hypoxia signaling pathway\n                    <jats:italic>in vivo<\/jats:italic>\n                    , including its role in the endocrine system, especially in adrenal tumors.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2022.1103075","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T10:16:40Z","timestamp":1673259400000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Hypoxia signaling pathway: A central mediator in endocrine tumors"],"prefix":"10.3389","volume":"13","author":[{"given":"Deepika","family":"Watts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh T.","family":"Jaykar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bechmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Wielockx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2012.06.004","article-title":"Passing the baton: the HIF switch","volume":"37","author":"Koh","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810067106","article-title":"Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis","volume":"106","author":"Xia","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314427","article-title":"High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq","volume":"117","author":"Schodel","year":"2011","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402310","article-title":"A microRNA component of the hypoxic response","volume":"15","author":"Kulshreshtha","year":"2008","journal-title":"Cell Death Differ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.07.012","article-title":"Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition","volume":"43","author":"Wu","year":"2011","journal-title":"Mol Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3621","article-title":"bHLH-PAS proteins in cancer","volume":"13","author":"Bersten","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304982200","article-title":"Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor","volume":"278","author":"Hirsil\u00e4","year":"2003","journal-title":"J Biol Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg392","article-title":"HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia","volume":"22","author":"Berra","year":"2003","journal-title":"EMBO J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"re12","DOI":"10.1126\/stke.3062005re12","article-title":"Integration of oxygen signaling at the consensus HRE","volume":"2005","author":"Wenger","year":"2005","journal-title":"Sci STKE 2005"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4564","article-title":"The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha","volume":"66","author":"Dayan","year":"2006","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2005.05.001","article-title":"Negative and positive regulation of HIF-1: a complex network","volume":"1755","author":"B\u00e1rdos","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2004.08.012","article-title":"Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators","volume":"37","author":"D\u00e9ry","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00015-07","article-title":"Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner","volume":"27","author":"Fl\u00fcgel","year":"2007","journal-title":"Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300763200","article-title":"Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase\/Akt\/glycogen synthase kinase 3beta pathway in HepG2 cells","volume":"278","author":"Mottet","year":"2003","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375014","article-title":"GSK-3\u03b2 regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1\u03b1","volume":"119","author":"Fl\u00fcgel","year":"2012","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.160325","article-title":"Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha","volume":"285","author":"Xu","year":"2010","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.10.030","article-title":"mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1\u03b1","volume":"40","author":"Cam","year":"2010","journal-title":"Mol Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)01181-9","article-title":"ERK activation upon hypoxia: involvement in HIF-1 activation","volume":"468","author":"Minet","year":"2000","journal-title":"FEBS Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115703","article-title":"Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target","volume":"22","author":"Infantino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603675","article-title":"Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms","volume":"96","author":"Lau","year":"2007","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.004","article-title":"Differential but complementary HIF1\u03b1 and HIF2\u03b1 transcriptional regulation","volume":"26","author":"Downes","year":"2018","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"B31","article-title":"Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors","volume":"61","author":"Cairns","year":"2001","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2821","article-title":"Imaging cycling tumor hypoxia","volume":"70","author":"Matsumoto","year":"2010","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.11.045","article-title":"Hypoxia-mediated drug resistance in breast cancers","volume":"502","author":"McAleese","year":"2021","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030542","article-title":"The role of hypoxia in glioblastoma radiotherapy resistance","volume":"13","author":"Ch\u00e9deville","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist Update"},{"key":"B36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1053-4296(96)80035-X","article-title":"Hypoxic stress proteins: Survival of the fittest","volume":"6","author":"Giaccia","year":"1996","journal-title":"Semin Radiat Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/379088a0","article-title":"Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours","volume":"379","author":"Graeber","year":"1996","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34025-4_11","article-title":"Melanoma metabolism: Cell survival and resistance to therapy","volume":"1219","author":"Luis","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B40","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00082","article-title":"Metabolic reprogramming in thyroid carcinoma","volume":"8","author":"Coelho","year":"2018","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1556\/OH.2013.29706","article-title":"[Genetics of neuroendocrine tumours, hereditary tumour syndromes]","volume":"154","author":"Igaz","year":"2013","journal-title":"Orv Hetil"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030467","article-title":"Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: Do they work","volume":"14","author":"Jimenez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3826","article-title":"Silencing of hypoxia-inducible factor-1alpha promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2","volume":"12","author":"Ding","year":"2016","journal-title":"Exp Ther Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1159\/000457479","article-title":"Hypoxia pathway mutations in pheochromocytomas and paragangliomas","volume":"150","author":"Amorim-Pires","year":"2016","journal-title":"Cytogenet Genome Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00040","article-title":"Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment","volume":"9","author":"Sormendi","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050988","article-title":"HIF-prolyl hydroxylase domain proteins (PHDs) in cancer-potential targets for anti-tumor therapy","volume":"13","author":"Gaete","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on Adrenal Tumours in 2017 World Health Organization (Who) of Endocrine Tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-5347(17)37119-7","article-title":"Extra-adrenal pheochromocytoma","volume":"147","author":"Whalen","year":"1992","journal-title":"J Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1636","article-title":"Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1\u03b1\/miR-210 signaling pathway","volume":"98","author":"Merlo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000634","article-title":"Genetics of pheochromocytoma and paraganglioma","volume":"28","author":"Wachtel","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031450","article-title":"Genetics of pheochromocytomas and paragangliomas determine the therapeutical approach","volume":"23","author":"Sarkadi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/CCO.0000000000000694","article-title":"An update on adult forms of hereditary pheochromocytomas and paragangliomas","volume":"33","author":"Dariane","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2\u03b1 supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/bies.200900122","article-title":"Eukaryotic cold shock domain proteins: highly versatile regulators of gene expression","volume":"32","author":"Mihailovich","year":"2010","journal-title":"Bioessays"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210068","article-title":"Unr, a cytoplasmic RNA-binding protein with cold-shock domains, is involved in control of apoptosis in ES and HuH7 cells","volume":"26","author":"Dormoy-Raclet","year":"2007","journal-title":"Oncogene"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00515","article-title":"Update of pheochromocytoma syndromes: Genetics, biochemical evaluation, and imaging","volume":"9","author":"Alrezk","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11886-019-1184-y","article-title":"Pheochromocytoma\/Paraganglioma: Is this a genetic disorder","volume":"21","author":"Fishbein","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0294","article-title":"Pheochromocytomas and paragangliomas in von hippel-lindau disease: not a needle in a haystack","volume":"10","author":"Castro-Teles","year":"2021","journal-title":"Endocr Connect"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050667","article-title":"A transgenic mouse model of pacak(-)Zhuang syndrome with an Epas1 gain-of-Function mutation","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"31","author":"Pacak","year":"2013","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J Mol Med"},{"key":"B68","article-title":"Chapter 10 - Von hippel\u2013lindau disease","volume-title":"Handbook of clinical neurology","author":"Chittiboina","year":"2015"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00867","article-title":"Frequent mutations of VHL gene and the clinical phenotypes in the largest Chinese cohort with Von hippel-lindau disease","volume":"10","author":"Hong","year":"2019","journal-title":"Front Genet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0167","article-title":"Novel genotype-phenotype correlations in five Chinese families with Von hippel-lindau disease","volume":"7","author":"Liu","year":"2018","journal-title":"Endocr Connect"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020362","article-title":"The role of VHL in the development of von hippel-lindau disease and erythrocytosis","volume":"13","author":"Hudler","year":"2022","journal-title":"Genes (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1159\/000345668","article-title":"Von hippel-lindau syndrome","volume":"41","author":"Chou","year":"2013","journal-title":"Front Horm Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0359-4","article-title":"Abdominal visceral lesions in von hippel-lindau disease: Incidence and clinical behavior of pancreatic and adrenal lesions at a single center","volume":"30","author":"Delman","year":"2006","journal-title":"World J Surg"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2010.175","article-title":"Von hippel\u2013lindau disease: A clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162480","article-title":"Von Hippel-lindau disease: insights into oxygen sensing, protein degradation, and cancer","volume":"132","author":"Kaelin","year":"2022","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.10.1019","article-title":"Von hippel-lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF","volume":"10","author":"Hoffman","year":"2001","journal-title":"Hum Mol Genet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.15586\/jkcvhl.v9i1.206","article-title":"Von Hippel-lindau syndrome: Medical syndrome or surgical syndrome? a surgical perspective","volume":"9","author":"Coco","year":"2022","journal-title":"J Kidney Cancer VHL"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nat Genet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1755-8794-5-48","article-title":"Integrative analysis of neuroblastoma and pheochromocytoma genomics data","volume":"5","author":"Szab\u00f3","year":"2012","journal-title":"BMC Med Genomics"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.153320","article-title":"Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma","volume":"57","author":"Eisenhofer","year":"2011","journal-title":"Clin Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.901760","article-title":"Biochemical diagnosis of catecholamine-producing tumors of childhood: Neuroblastoma, pheochromocytoma and paraganglioma","volume":"13","author":"Eisenhofer","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1899","article-title":"Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas","volume":"90","author":"Vogel","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28868","article-title":"Opposing effects of HIF1alpha and HIF2alpha on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X","volume":"135","author":"Qin","year":"2014","journal-title":"Int J Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41419-021-03731-7","article-title":"GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma\/paraganglioma","volume":"12","author":"Dong","year":"2021","journal-title":"Cell Death Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.06.015","article-title":"Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer","volume":"8","author":"Lee","year":"2005","journal-title":"Cancer Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2010.01464.x","article-title":"Clinical and functional properties of novel VHL mutation (X214L) consistent with type 2A phenotype and low risk of renal cell carcinoma","volume":"79","author":"Sorrell","year":"2011","journal-title":"Clin Genet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1593\/neo.122132","article-title":"Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas","volume":"15","author":"Shankavaram","year":"2013","journal-title":"Neoplasia"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01762","article-title":"Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: A nationwide study","volume":"103","author":"van der Tuin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0346","article-title":"Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas","volume":"27","author":"Moog","year":"2020","journal-title":"Endocr Relat Cancer 27"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01639-8","article-title":"The functional roles of TCA cycle metabolites in cancer","volume":"40","author":"Eniafe","year":"2021","journal-title":"Oncogene"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","article-title":"TET-mediated hypermethylation primes SDH-deficient cells for HIF2\u03b1-driven mesenchymal transition","volume":"30","author":"Morin","year":"2020","journal-title":"Cell Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020525","article-title":"Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma","volume":"87","author":"Gimenez-Roqueplo","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas","volume":"18","author":"Welander","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"New Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3324\/haematol.2011.044644","article-title":"Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia","volume":"97","author":"Ladroue","year":"2012","journal-title":"Haematologica"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58081113","article-title":"Novel germline PHD2 variant in a metastatic pheochromocytoma and chronic myeloid leukemia, but in the absence of polycythemia","volume":"58","author":"Provenzano","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0211","article-title":"Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma","volume":"28","author":"Eckardt","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.586857","article-title":"The VHL\/HIF axis in the development and treatment of Pheochromocytoma\/Paraganglioma","volume":"11","author":"Peng","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207669","article-title":"Head and neck paragangliomas-a genetic overview","volume":"41","author":"Majewska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med Res Rev"},{"key":"B103","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41419-021-04089-6","article-title":"USP14 maintains HIF1-\u03b1 stabilization via its deubiquitination activity in hepatocellular carcinoma","volume":"12","author":"Lv","year":"2021","journal-title":"Cell Death Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22449","article-title":"HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies","volume":"56","author":"Gladek","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Comino-Mendez","year":"2013","journal-title":"Hum Mol Genet"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050594","article-title":"Impact of extrinsic and intrinsic hypoxia on catecholamine biosynthesis in absence or presence of Hif2alpha in pheochromocytoma cells","volume":"11","author":"Bechmann","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.01696.x","article-title":"Regulation of tyrosine hydroxylase promoter activity by the von hippel-lindau tumor suppressor protein and hypoxia-inducible transcription factors","volume":"85","author":"Schnell","year":"2003","journal-title":"J Neurochem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06153.x","article-title":"Hypoxia inducible factor (HIF)-2\u03b1 is required for the development of the catecholaminergic phenotype of sympathoadrenal cells","volume":"110","author":"Brown","year":"2009","journal-title":"J Neurochem"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-021-02121-y","article-title":"HIF2alpha regulates the synthesis and release of epinephrine in the adrenal medulla","volume":"99","author":"Watts","year":"2021","journal-title":"J Mol Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/82_2010_72","article-title":"The HIF-2\u03b1-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization","volume":"345","author":"Pietras","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.08.026","article-title":"Recruitment of HIF-1\u03b1 and HIF-2\u03b1 to common target genes is differentially regulated in neuroblastoma: HIF-2\u03b1 promotes an aggressive phenotype","volume":"10","author":"Holmquist-Mengelbier","year":"2006","journal-title":"Cancer Cell"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMc1211953","article-title":"HIF2A mutations in paraganglioma with polycythemia","volume":"367","author":"Favier","year":"2012","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/ERC-13-0384","article-title":"Frequent EPAS1\/HIF2\u03b1 exons 9 and 12 mutations in non-familial pheochromocytoma","volume":"21","author":"Welander","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-137703","article-title":"Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis","volume":"111","author":"Percy","year":"2008","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073123","article-title":"A gain-of-function mutation in the HIF2A gene in familial erythrocytosis","volume":"358","author":"Percy","year":"2008","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1394553","article-title":"HIF2A germline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma","volume":"18","author":"Liu","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12022-017-9469-4","article-title":"A somatic HIF2\u03b1 mutation-induced multiple and recurrent Pheochromocytoma\/Paraganglioma with polycythemia: Clinical study with literature review","volume":"28","author":"Liu","year":"2017","journal-title":"Endocr Pathol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2600","article-title":"Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome","volume":"99","author":"Buffet","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B121","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1677\/erc.1.00838","article-title":"Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von hippel-lindau syndrome","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"101415","DOI":"10.1016\/j.beem.2020.101415","article-title":"New perspectives for mitotane treatment of adrenocortical carcinoma","volume":"34","author":"Puglisi","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B123","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.trecan.2016.05.006","article-title":"Hypoxia: Signaling the metastatic cascade","volume":"2","author":"Rankin","year":"2016","journal-title":"Trends Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41467-021-21687-2","article-title":"Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response","volume":"12","author":"Andrysik","year":"2021","journal-title":"Nat Commun"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1159\/000282852","article-title":"Erythropoietin-producing adrenocortical carcinoma","volume":"56","author":"Oka","year":"1996","journal-title":"Urologia Internationalis"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2298973","DOI":"10.1155\/2021\/2298973","article-title":"And tumor immune microenvironment in adrenocortical carcinoma","volume":"2021","author":"Chen","year":"2021","journal-title":"J Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.856606","article-title":"A novel predictive model for adrenocortical carcinoma based on hypoxia- and ferroptosis-related gene expression","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-022-01735-z","article-title":"Update on the genetics of primary aldosteronism and aldosterone-producing adenomas","volume":"24","author":"Pitsava","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/gs.2019.10.22","article-title":"Primary aldosteronism diagnostics: KCNJ5 mutations and hybrid steroid synthesis in aldosterone-producing adenomas","volume":"9","author":"Rege","year":"2020","journal-title":"Gland Surg"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-011-0132-1","article-title":"Corticomedullary mixed tumor of the adrenal gland\u2013a clinical and pathological chameleon: case report and review of literature","volume":"65","author":"Donatini","year":"2013","journal-title":"Updates Surg"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.04.003","article-title":"Stemness regulation of the adrenal mixed corticomedullary tumorigenesis-a case-control study","volume":"22","author":"Chiou","year":"2020","journal-title":"Neoplasia"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherma","year":"2003","journal-title":"Lancet"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncol 69(suppl"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2020.409","article-title":"Immunohistochemical expression and prognostic significance of VEGF-c in well-differentiated thyroid cancer","volume":"16","author":"Ceric","year":"2020","journal-title":"Acta Endocrinol (Buchar)"},{"key":"B135","first-page":"1740","article-title":"Overexpression of HIF-2\u03b1, TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma","author":"Wang","year":"2013"},{"key":"B136","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00428-013-1484-3","article-title":"Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis","volume":"463","author":"Koperek","year":"2013","journal-title":"Virchows Archiv"},{"key":"B137","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12957-016-0785-9","article-title":"Expression of HIF-1alpha and HIF-2alpha correlates to biological and clinical significance in papillary thyroid carcinoma","volume":"14","author":"Liu","year":"2016","journal-title":"World J Surg Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1677\/ERC-08-0251","article-title":"Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas","volume":"17","author":"Burrows","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"762905","DOI":"10.4061\/2011\/762905","article-title":"Hypoxia-inducible factor in thyroid carcinoma","volume":"2011","author":"Burrows","year":"2011","journal-title":"J Thyroid Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"B141","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B142","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2020.03.09","article-title":"Inherited syndromes involving pancreatic neuroendocrine tumors","volume":"11","author":"Geurts","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.678869","article-title":"Phakomatoses and endocrine gland tumors: Noteworthy and (Not so) rare associations","volume":"12","author":"Chevalier","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"B146","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41419-018-0367-6","article-title":"TCF7L2 positively regulates aerobic glycolysis via the EGLN2\/HIF-1alpha axis and indicates prognosis in pancreatic cancer","volume":"9","author":"Xiang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B147","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-017-0689-5","article-title":"Hypoxia-inducible factor-2\u03b1 promotes tumor progression and has crosstalk with wnt\/\u03b2-catenin signaling in pancreatic cancer","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol Cancer"},{"key":"B148","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/1566524016666160316153623","article-title":"VEGF promotes glycolysis in pancreatic cancer via HIF1\u03b1 up-regulation","volume":"16","author":"Shi","year":"2016","journal-title":"Curr Mol Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/genes12050698","article-title":"Essential role of the 14q32 encoded miRNAs in endocrine tumors","volume":"12","author":"Krokker","year":"2021","journal-title":"Genes"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0183","article-title":"Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways","volume":"20","author":"de Cubas","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku515","article-title":"MicroRNA-382 induced by HIF-1\u03b1 is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog","volume":"42","author":"Seok","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0142","article-title":"MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets","volume":"17","author":"Meyer-Rochow","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.82","article-title":"C-myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2\u03b1 and promotes tumor angiogenesis and metastasis by upregulating FGF2","volume":"34","author":"Xue","year":"2015","journal-title":"Oncogene"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35458","article-title":"Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p\/TSC2\/mTOR axis in metastatic pheochromocytoma\/paraganglioma","volume":"9","author":"Calsina","year":"2019","journal-title":"Theranostics"},{"key":"B155","article-title":"Role of miR-101 in pheochromocytoma patients with SDHD mutation","volume":"8","author":"Zong","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052413","article-title":"Overexpression of miR-375 and l-type amino acid transporter 1 in pheochromocytoma and their molecular and functional implications","volume":"23","author":"Manso","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.647369","article-title":"Serum miR-375 for diagnostic and prognostic purposes in medullary thyroid carcinoma","volume":"12","author":"Censi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.03.004","article-title":"Mir-210\u2013Micromanager of the Hypoxia Pathway","volume":"16","author":"Huang","year":"2010","journal-title":"Trends Mol Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0519","article-title":"Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours","volume":"21","author":"Tsang","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2410","article-title":"Identification of a signaling axis HIF-1\u03b1\/microRNA-210\/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas","volume":"97","author":"Merlo","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071522","article-title":"MicroRNAs, long non-coding RNAs, and circular RNAs: Potential biomarkers and therapeutic targets in Pheochromocytoma\/Paraganglioma","volume":"13","author":"Turai","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9059-x","article-title":"Targeting hypoxia cell signaling for cancer therapy","volume":"26","author":"Melillo","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"B163","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0895","article-title":"Molecular pathways: Hypoxia-activated prodrugs in cancer therapy","volume":"23","author":"Baran","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A small-molecule antagonist of HIF2\u03b1 is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2533374100","article-title":"Structural basis for PAS domain heterodimerization in the basic helix\u2013loop\u2013helix-PAS transcription factor hypoxia-inducible factor","volume":"100","author":"Erbel","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-Class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"C9","DOI":"10.1530\/ERC-16-0479","article-title":"New HIF2\u03b1 inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas","volume":"24","author":"Toledo","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma","volume":"62","author":"Xu","year":"2019","journal-title":"J Medicinal Chem"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007094","article-title":"The warburg effect is genetically determined in inherited pheochromocytomas","volume":"4","author":"Favier","year":"2009","journal-title":"PLos One"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1055\/a-1526-5263","article-title":"Hypoxia-inducible factor 2alpha: A key player in tumorigenesis and metastasis of pheochromocytoma and paraganglioma","volume":"130","author":"Bechmann","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1103075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T10:16:47Z","timestamp":1673259407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1103075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":174,"alternative-id":["10.3389\/fendo.2022.1103075"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1103075","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1103075"}}